AI Article Synopsis
- CD20×CD3 bispecific antibodies, like glofitamab, are successful in treating systemic B-cell lymphomas but their effectiveness against central nervous system (CNS) lymphoma is unclear.
- The study shows that glofitamab can penetrate the blood-brain barrier, allowing it to reach CNS tumors.
- It also promotes immune-cell infiltration and has resulted in positive clinical responses in patients with secondary CNS lymphoma.
Article Abstract
Although CD20×CD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in central nervous system (CNS) lymphoma is unknown. Here, we report the CD20×CD3 bispecific glofitamab penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces clinical responses in patients with secondary CNS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302446 | PMC |
| http://dx.doi.org/10.1182/blood.2024024168 | DOI Listing |
Publication Analysis
Top Keywords
infiltration cns
8
cns tumors
8
tumors induces
8
induces clinical
8
clinical responses
8
secondary cns
8
cns lymphoma
8
cd20×cd3 bispecific
8
cns
5
glofitamab stimulates
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!